6/12/2013

The FDA granted orphan-drug status to Stemline Therapeutics' SL-401, an experimental drug for aggressive hematologic malignancy blastic plasmacytoid dendritic cell neoplasm. The drug, which also holds an orphan designation for acute myeloid leukemia, targets the interleukin-3 receptor on cancerous cells.

Related Summaries